Measuring erythrocyte sedimentation rate, angiopoietin-2/-1 ratio, and matrix metalloprotease-3 levels may help discriminate patients with isolated polymyalgia rheumatica from those with concomitant giant cell arteritis, research suggests.

Findings from a proof-of-concept trial provide preliminary evidence to suggest that the JAK inhibitor baricitinib is well tolerated and may have efficacy for the treatment of relapsing giant cell arteritis.

Cumulative prednisone dose and effective disease control are both associated with increased BMI among patients with giant cell arteritis, post-hoc analysis of the GiACTA trial suggests.

Findings from the phase 2 TitAIN trial support further investigation of the IL-17A inhibitor secukinumab for the treatment of giant cell arteritis.

The majority of patients with giant cell arteritis generate an antibody response following both doses of the Pfizer–BioNTech COVID-19 vaccine, researchers report in a letter to Rheumatology .

Tocilizumab monotherapy following an ultra-short pulse of glucocorticoid treatment may be effective for inducing and maintaining remission in patients with new-onset giant cell arteritis, suggest preliminary study findings.

Mavrilimumab is effective for reducing the risk for flare and maintaining sustained remission in patients with giant cell arteritis, phase 2 study findings show.

More than a third of patients with giant cell arteritis remission who discontinue tocilizumab treatment after 1 year remain in clinical remission for a further 2 years, suggest follow-up results from the GiACTA trial.

Imaging with a combined positron emission tomography and computed tomography scanner shows good accuracy for diagnosing giant cell arteritis versus the gold-standard temporal artery biopsy.

Imaging with a combined positron emission tomography and computed tomography scanner shows good accuracy for diagnosing giant cell arteritis versus the gold-standard temporal artery biopsy.

Mounié M et al. Arthritis Care Res 2018. doi: 10.1002/acr.23736

Vascular ultrasound could be a contender as a first-line imaging test for diagnosing large vessel giant cell arteritis, suggests research.

Vascular ultrasound could be a contender as a first-line imaging test for diagnosing large vessel giant cell arteritis, suggests research.

Preliminary study results suggest that the interleukin-12/23 inhibitor ustekinumab may be a promising treatment option for patients with giant cell arteritis.

Berit Dalsgaard Nielsen discusses Aarhus University study findings showing the potential for ultrasound as a first-line imaging test for diagnosing large vessel inflammation in patients with suspected giant cell arteritis (4:57).

Oh LJ et al. Intern Med J 2018; 48: 408–413. doi: 10.1111/imj.13713

Ciccia F et al. Rheumatology (Oxford) 2018; Advance online publication. doi: 10.1093/rheumatology/key106